Scottsdale, AZ (PRWEB) February 4, 2010
MedPredict Market Research, a global provider of pharmaceutical competitive intelligence and market research, has published a new report providing critical strategic insight for companies marketing and developing anticoagulant therapies. This report is based on primary interviews conducted with cardiovascular experts from North America and Europe immediately following the American Society of Hematology conference held in December, 2009.
“Our panel weighs in on the key anticoagulants clinical trial data presented at ASH and distills a large amount of information down to the most critical insights drug developers in this space should have for decision-making,” according to Dr. Jeff Berk, the report's author.
"Together, the insights from these interviews can be thought of as a “war-game,” laying out the competitive strengths and weaknesses of marketed products and experimental therapeutics with high likelihood of being commercialized," continued Dr. Berk. "In this report, the panelists differentiate each drug based on clinical trial design, anticoagulant efficacy, increased bleeding risk, convenience, associated therapeutic limitations and costs."
Companies mentioned in this report include: AstraZeneca, Atritech, Bayer Schering/Johnson & Johnson, Boehringer Ingelheim, Bristol-Meyers Squibb, Daiichi Sankyo, Lilly, Merck/Schering-Plough, Novartis, Pfizer, Portola, Sanofi-Aventis and Takeda.
This report can be purchased by contacting MedPredict (http://www.medpredict.com) or calling (513) 271-1924.
MedPredict maintains a proprietary database of over 1,000 global physician thought leaders, including 40+ specialties in 30+ therapeutic categories. Based on primary interviews with these thought leaders, MedPredict publishes periodic reports in each category to keep clients up-to-date on emerging trends and competitive activity. The reports include thought leader reactions to recent publications and medical conferences, as well as clinical, regulatory and marketing activity.